Lonza completed the expansion of its small molecules production facility in Bend, Oregon, as part of the Swiss CDMO’s plans to enhance its solid form services.
The project included the remodeling of laboratory space used to develop early-stage compounds. The site supports solid form screening and characterization of small-molecule active pharmaceutical ingredients plus selection and early crystallization process development, the company said in a release.
Lonza didn't reveal financial details of the expansion.
On a bigger scale, the company in May 2021 said it would spend $1 billion and hire as many as 550 people in the U.S. and Europe as part of its growth strategy.
In a separate announcement, Lonza said it inked collaboration deals with McSAF and Cristal Therapeutics to expand its bioconjugate offerings.
Cristal Therapeutics' CliCr technology is a novel class of bio-orthogonal reagents that supports a large range of bioconjugates. McSAF’s Inside Technology allows for the fast and efficient generation of homogeneous and stable antibody-drug conjugates from native antibodies.